Gilead Sciences Incorporated (NASDAQ:GILD) Just Reported Decreased Shorts

January 20, 2018 - By Linda Rogers

 Gilead Sciences Incorporated (NASDAQ:GILD) Just Reported Decreased Shorts

Investors sentiment increased to 1.03 in Q3 2017. Its up 0.10, from 0.93 in 2017Q2. It is positive, as 96 investors sold Gilead Sciences, Inc. shares while 488 reduced holdings. 127 funds opened positions while 474 raised stakes. 957.62 million shares or 2.06% more from 938.32 million shares in 2017Q2 were reported.
Mawer Management accumulated 578,170 shares. Columbia Partners L L C Inv Management holds 0.03% in Gilead Sciences, Inc. (NASDAQ:GILD) or 2,986 shares. Baystate Wealth Mngmt Limited Liability Com holds 937 shares or 0.01% of its portfolio. Kbc Grp Incorporated Nv has invested 0.55% in Gilead Sciences, Inc. (NASDAQ:GILD). Klingenstein Fields And Co Limited Company holds 19,050 shares or 0.06% of its portfolio. Kames Cap Public Limited owns 449,753 shares or 1% of their US portfolio. Old National Savings Bank In owns 0.14% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 32,092 shares. Fukoku Mutual Life reported 6,600 shares. California-based Btr Mngmt Inc has invested 0.75% in Gilead Sciences, Inc. (NASDAQ:GILD). Bartlett And Com Lc holds 302,079 shares. Tower Rech Cap Lc (Trc) invested in 0.03% or 4,864 shares. Dreman Value Mgmt L L C stated it has 0.49% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Fayez Sarofim And holds 0.11% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD) for 250,271 shares. Boston Advsr reported 0.68% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Domini Impact Invests Ltd Liability Company holds 8.62% in Gilead Sciences, Inc. (NASDAQ:GILD) or 4,681 shares.

Since August 1, 2017, it had 0 insider buys, and 12 selling transactions for $43.50 million activity. $4.99 million worth of Gilead Sciences, Inc. (NASDAQ:GILD) was sold by Meyers James R. $1.11M worth of Gilead Sciences, Inc. (NASDAQ:GILD) was sold by Alton Gregg H on Tuesday, January 2. 51,820 shares were sold by Washington Robin L, worth $4.40M.

The stock of Gilead Sciences Incorporated (NASDAQ:GILD) registered a decrease of 1.79% in short interest. GILD’s total short interest was 19.63M shares in January as published by FINRA. Its down 1.79% from 19.99 million shares, reported previously. With 6.54 million shares average volume, it will take short sellers 3 days to cover their GILD’s short positions. The short interest to Gilead Sciences Incorporated’s float is 1.51%.

The stock decreased 0.23% or $0.19 during the last trading session, reaching $80.98. About 7.92 million shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 21.80% since January 20, 2017 and is downtrending. It has underperformed by 38.50% the S&P500.

Gilead Sciences, Inc. discovers, develops, and commercializes medicines in the areas of unmet medical needs in Europe, North America, Asia, South America, Africa, Australia, India, and the Middle East. The company has market cap of $105.78 billion. The companyÂ’s products include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus infection in adults; and Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It has a 9.22 P/E ratio. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B.

Gilead Sciences, Inc. (NASDAQ:GILD) Ratings Coverage

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 19 have Buy rating, 0 Sell and 11 Hold. Therefore 63% are positive. Gilead Sciences had 112 analyst reports since July 29, 2015 according to SRatingsIntel. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned “Outperform” rating by RBC Capital Markets on Monday, October 3. The firm has “Market Perform” rating by Leerink Swann given on Thursday, October 19. As per Monday, August 28, the company rating was maintained by BMO Capital Markets. The firm has “Buy” rating by Citigroup given on Thursday, February 25. The rating was downgraded by Argus Research to “Hold” on Friday, July 29. The firm has “Buy” rating given on Wednesday, October 18 by Cowen & Co. The firm has “Neutral” rating given on Wednesday, October 4 by Bank of America. Maxim Group maintained the stock with “Hold” rating in Thursday, July 27 report. BMO Capital Markets maintained Gilead Sciences, Inc. (NASDAQ:GILD) on Thursday, July 27 with “Hold” rating. The company was maintained on Thursday, October 5 by Leerink Swann.

More notable recent Gilead Sciences, Inc. (NASDAQ:GILD) news were published by: Fool.com which released: “Why 2017 Was a Year to Remember for Gilead Sciences, Inc.” on January 05, 2018, also Seekingalpha.com with their article: “Gilead: Buy Or Wait?” published on January 08, 2018, Fool.com published: “2017 Was a Year to Forget for Gilead Sciences, Inc., but This Year Could Be Better” on January 12, 2018. More interesting news about Gilead Sciences, Inc. (NASDAQ:GILD) were released by: Omaha.com and their article: “On Investments: CVS, Gilead Sciences hit the Casualty List” published on January 16, 2018 as well as Finance.Yahoo.com‘s news article titled: “Gilead Collaborates with Pfizer for Yescarta Combo Study” with publication date: January 19, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: